Save the Date- ACI’s Summit on Life Sciences Patents is Back!

ACI’s 18th Annual Advanced Summit on Life Sciences Patents returns to New York this May to provide practical insights on how to maximize patent life cycles and develop strategies to enhance patent portfolio protections.

By amalgamating the practical experiences and unique insights of leading in-house IP counsel, patent prosecutors and litigators, the USPTO, and policy experts from both sides of the Atlantic, this conference is a must-attend industry event.

Heather Boussios
Assistant General Counsel – IP
Aptevo Therapeutics

Gloria Fuentes
Executive Director, Corporate Transactions
Merck

 

Yu Ming Dammann
Associate General Counsel
Gilead Sciences
Jeffrey Kopacz
Vice President IP
Omega Therapeutics

 

Brendan M. O’Malley
Vice President, Chief IP Counsel
Abeona Therapeutics Inc.
Guido Pontremoli
Corporate IP Patent Director
Chiesi Farmaceutici S.P.A

Co-chair, Leslie Fischer (Principal Patent Attorney, Novartis) shared why she believes this conference is a must-attend:

“ACI’s Life Sciences Patent conference is absolutely my go-to conference every year – one I simply do not miss. The panels are excellent and always on point, with timely topics and engaging speakers. And, although held in NYC, this conference provides global patent insights.

We’ve had speakers from all over the world, talking about issues as diverse as Brexit and the Unified Patent Court, sufficiency issues for antibodies in Japan, patent extensions in Canada, and double patenting in the U.S. If you only go to one patent event for life sciences in 2020, this should be it.”

Interested parties are encouraged to take advantage of the early bird discounts and reserve your seat today! Seats are going quickly.

 

Share

Warning & Disclaimer: The pages, articles and comments on IPWatchdog.com do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of IPWatchdog.com.

Join the Discussion

No comments yet.